76,210 Shares in Boston Scientific Corporation $BSX Bought by Wealthfront Advisers LLC

Wealthfront Advisers LLC bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 76,210 shares of the medical equipment provider’s stock, valued at approximately $3,253,000.

Several other large investors also recently modified their holdings of BSX. Brighton Jones LLC increased its stake in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. FWL Investment Management LLC bought a new stake in shares of Boston Scientific during the second quarter worth $26,000. Main Street Financial Solutions LLC increased its position in shares of Boston Scientific by 35.3% during the second quarter. Main Street Financial Solutions LLC now owns 7,556 shares of the medical equipment provider’s stock worth $812,000 after acquiring an additional 1,971 shares in the last quarter. Ieq Capital LLC raised its holdings in shares of Boston Scientific by 97.0% during the second quarter. Ieq Capital LLC now owns 123,592 shares of the medical equipment provider’s stock worth $13,275,000 after acquiring an additional 60,860 shares during the period. Finally, HUB Investment Partners LLC lifted its position in Boston Scientific by 56.2% in the 2nd quarter. HUB Investment Partners LLC now owns 7,102 shares of the medical equipment provider’s stock valued at $763,000 after acquiring an additional 2,556 shares in the last quarter. 89.07% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director Edward J. Ludwig purchased 5,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 31st. The stock was purchased at an average cost of $45.48 per share, with a total value of $227,400.00. Following the completion of the transaction, the director owned 30,359 shares of the company’s stock, valued at approximately $1,380,727.32. This trade represents a 19.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was bought at an average price of $47.59 per share, with a total value of $99,939.00. Following the completion of the purchase, the director owned 17,160 shares of the company’s stock, valued at approximately $816,644.40. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders purchased 194,522 shares of company stock worth $9,385,210 in the last quarter. Corporate insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Shares of BSX opened at $49.47 on Friday. The stock has a market capitalization of $71.69 billion, a price-to-earnings ratio of 20.03, a PEG ratio of 1.13 and a beta of 0.56. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The firm has a fifty day simple moving average of $46.26 and a 200 day simple moving average of $57.91. The company has a current ratio of 1.24, a quick ratio of 0.74 and a debt-to-equity ratio of 0.43.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same period in the previous year, the business earned $0.75 EPS. The company’s revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. Research analysts forecast that Boston Scientific Corporation will post 3.3 EPS for the current fiscal year.

Boston Scientific declared that its board has authorized a stock repurchase plan on Monday, May 18th that permits the company to repurchase $5.00 billion in shares. This repurchase authorization permits the medical equipment provider to repurchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company’s management believes its shares are undervalued.

Analyst Ratings Changes

A number of brokerages recently weighed in on BSX. Stifel Nicolaus set a $60.00 target price on shares of Boston Scientific in a research note on Wednesday, July 29th. Daiwa Securities Group downgraded Boston Scientific from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Citigroup cut their price target on Boston Scientific from $70.00 to $61.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Mizuho reduced their price objective on Boston Scientific from $90.00 to $70.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Finally, TD Cowen decreased their price objective on Boston Scientific from $61.00 to $56.00 and set a “buy” rating for the company in a report on Thursday, July 30th. Twenty-four investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $71.62.

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.